Quick Answer Altimmune, Inc. reported Shares Outstanding of 110.88 million shares for fiscal year 2025. Altimmune, Inc. Shares Outstanding — Annual History Fiscal Year Shares Outstanding YoY Change 2025 110.88M +53.3% 2024 72.35M +2.4% 2023 70.68M +43.7% 2022 49.20M +20.0% 2021 40.99M +10.4% 2020 37.14M +142.6% 2019 15.31M +68.7% 2018 9.08M +1391.9% 2017 608,499 -91.2% … Read more
Quick Answer Altimmune, Inc. reported R&D Expense of $66.43 million for fiscal year 2025. Altimmune, Inc. R&D Expense — Annual History Fiscal Year R&D Expense YoY Change 2025 $66.43M -19.2% 2024 $82.23M +25.0% 2023 $65.80M -6.7% 2022 $70.54M -5.4% 2021 $74.54M +49.8% 2020 $49.77M +180.2% 2019 $17.77M -3.8% 2018 $18.46M +0.3% 2017 $18.41M +154.9% 2016 … Read more
Quick Answer Altimmune, Inc. reported Stockholders Equity of $224.89 million for fiscal year 2025. Altimmune, Inc. Stockholders Equity — Annual History Fiscal Year Stockholders Equity YoY Change 2025 $224.89M +82.1% 2024 $123.51M -36.4% 2023 $194.10M +4.8% 2022 $185.29M -7.0% 2021 $199.13M -11.8% 2020 $225.88M +396.2% 2019 $45.52M -5.8% 2018 $48.31M +22.6% 2017 $39.40M +22.3% 2016 … Read more
Quick Answer Altimmune, Inc. reported Long-Term Debt of $34.29 million for fiscal year 2025. Altimmune, Inc. Long-Term Debt — Annual History Fiscal Year Long-Term Debt YoY Change 2025 $34.29M +4595.1% 2013 $730.3K -57.1% 2012 $1.70M — Quarterly Long-Term Debt Quarter Ending Long-Term Debt YoY QoQ September 30, 2025 $14.45M — +0.8% June 30, 2025 $14.33M … Read more
Quick Answer Altimmune, Inc. reported Cash and Equivalents of $43.76 million for fiscal year 2025. Altimmune, Inc. Cash and Equivalents — Annual History Fiscal Year Cash and Equivalents YoY Change 2025 $43.76M +18.5% 2024 $36.93M -72.7% 2023 $135.12M +21.6% 2022 $111.10M -41.6% 2021 $190.30M +64.2% 2020 $115.92M +1193.3% 2019 $8.96M -73.4% 2018 $33.72M +284.5% 2017 … Read more
Quick Answer Altimmune, Inc. reported Total Assets of $279.93 million for fiscal year 2025. Altimmune, Inc. Total Assets — Annual History Fiscal Year Total Assets YoY Change 2025 $279.93M +100.9% 2024 $139.31M -33.9% 2023 $210.64M +1.8% 2022 $206.93M -5.5% 2021 $218.87M -10.7% 2020 $245.12M +353.4% 2019 $54.06M -1.3% 2018 $54.75M -13.1% 2017 $63.03M +64.1% 2016 … Read more
Quick Answer Altimmune, Inc. reported Diluted EPS of $1.00 per share (loss) for fiscal year 2025. Altimmune, Inc. Diluted EPS — Annual History Fiscal Year Diluted EPS YoY Change 2025 -$1.00 +25.4% 2024 -$1.34 +19.3% 2023 -$1.66 +8.3% 2022 -$1.81 +23.0% 2021 -$2.35 -23.0% 2020 -$1.91 -164.7% 2016 $2.95 +6000.0% 2015 -$0.05 +70.6% 2014 -$0.17 … Read more
Quick Answer Altimmune, Inc. reported Net Income of -$88.09 million for fiscal year 2025. Altimmune, Inc. Net Income — Annual History Fiscal Year Net Income YoY Change 2025 -$88.09M +7.3% 2024 -$95.06M -7.5% 2023 -$88.45M -4.4% 2022 -$84.71M +12.7% 2021 -$97.09M -98.0% 2020 -$49.04M -139.0% 2019 -$20.52M +47.6% 2018 -$39.17M +15.6% 2017 -$46.43M -318.7% 2016 … Read more
Quick Answer Altimmune, Inc. reported Total Revenue of $41.0 thousand for fiscal year 2025. Altimmune, Inc. Total Revenue — Annual History Fiscal Year Total Revenue YoY Change 2025 $41.0K +105.0% 2024 $20.0K -95.3% 2023 $426.0K +726.5% 2022 -$68.0K -101.5% 2021 $4.41M -46.1% 2020 $8.19M +41.1% 2019 $5.80M -43.8% 2018 $10.33M -3.8% 2017 $10.74M +231.8% 2016 … Read more
Quick Answer Altimmune, Inc. reported Revenue (ASC 606) of $4.41 million for fiscal year 2021. Altimmune, Inc. Revenue (ASC 606) — Annual History Fiscal Year Revenue (ASC 606) YoY Change 2021 $4.41M -46.1% 2020 $8.19M +41.1% 2019 $5.80M -43.8% 2018 $10.33M -3.8% 2017 $10.74M — Quarterly Revenue (ASC 606) Quarter Ending Revenue (ASC 606) YoY … Read more